STOCK TITAN

[Form 4] NeueHealth, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Tomas Orozco, EVP Consumer Care of NeueHealth, Inc. (NEUE), reported transactions tied to the company's acquisition on 10/02/2025. The filing shows a disposition of 29,325 shares of common stock and the conversion/assumption of outstanding restricted stock units into parent-company units as part of a merger where the issuer became a wholly-owned subsidiary. In total 230,490 RSUs (2,490; 180,000; 48,000) were adjusted and continued under the parent entity's awards; none of the shares or resulting parent common-stock equivalents are reported as beneficially owned following the transactions. The disclosure also notes a Rollover Agreement that exchanged prior equity for common and preferred units of the acquiring holdings vehicle, and that certain RSUs retain existing vesting schedules, with a material vesting date on 10/11/2026.

Tomas Orozco, EVP Consumer Care di NeueHealth, Inc. (NEUE), ha riferito operazioni legate all'acquisizione della società in 10/02/2025. La dichiarazione mostra una cessione di 29.325 azioni ordinarie e la conversione/assunzione di unità azionarie vincolate rimanenti in unità controllate dalla casa madre come parte di una fusione in cui l'emittente è diventato una controllata interamente posseduta. In totale 230.490 RSU (2.490; 180.000; 48.000) sono stati adeguati e continuano sotto le stock award dell'entità madre; nessuna delle azioni o degli equivalenti di azioni ordinarie della capogruppo risultano detenuti in modo beneficio dopo le operazioni. La divulgazione segnala anche un Accordo di rollover che scambia capitale proprio precedente per azioni ordinarie e azion i privilegiate della holding acquirente, e che alcuni RSU mantengono i relativi piani di maturazione esistenti, con una data di maturazione rilevante 10/11/2026.

Tomas Orozco, EVP de Atención al Cliente de NeueHealth, Inc. (NEUE), informó transacciones relacionadas con la adquisición de la empresa en 10/02/2025. Los archivos muestran una disposición de 29,325 acciones ordinarias y la conversión/asunción de unidades restringidas de acciones en unidades de la empresa matriz como parte de una fusión en la que el emisor se convirtió en una subsidiaria de propiedad absoluta. En total se ajustaron y continuaron 230,490 RSU (2,490; 180,000; 48,000) bajo los premios de la entidad matriz; ninguna de las acciones o equivalentes de acciones comunes de la matriz resultantes se reportan como poseídas beneficiariamente después de las transacciones. La divulgación también señala un Acuerdo de rollover que intercambió capital previo por unidades comunes y preferentes de la holding adquirente, y que ciertos RSU conservan los calendarios de vesting existentes, con una fecha de vesting sustancial el 10/11/2026.

Tomas Orozco, NeueHealth, Inc. (NEUE)의 소비자 관리 부문 EVP가 회사의 인수와 관련된 거래를 10/02/2025에 보고했습니다. 공시는 합병의 일부로 발행인이 전액 소유 자회사가 된 경우에 해당하는 모회사 단위로의 이전/전환으로, 29,325 주의 보통주 처분 및 미확정 주식단위(RSU)의 전환/인수를 표시합니다. 총 230,490 RSU(2,490; 180,000; 48,000)가 조정되어 모회사 보상 하에서 계속되며, 거래 이후 어떤 주식이나 모회사 보통주 등가물도 유리하게 소유된 것으로 보고되지 않습니다. 또한 Rollover Agreement가 있어 이전 자본을 인수 보유 구조의 보통주 및 우선주로 교환했고, 일부 RSU는 기존 vesting 일정을 유지하며, 중요한 vesting 날짜는 10/11/2026입니다.

Tomas Orozco, EVP Consumer Care de NeueHealth, Inc. (NEUE), a signalé des transactions liées à l'acquisition de la société le 10/02/2025. Le document indique une cession de 29 325 actions ordinaires et la conversion/prise en charge des unités d’actions restreintes en unités de la société mère dans le cadre d’une fusion où l’émetteur est devenu une filiale à part entière. Au total, 230 490 RSU (2 490; 180 000; 48 000) ont été ajustés et poursuivis sous les récompenses de l’entité mère ; aucune des actions ou des équivalents d’actions ordinaires de la société mère ne sont déclarés comme détenus de manière bénéficiaire après les transactions. La divulgation mentionne également un Rollover Agreement qui échangeait les capitaux propres antérieurs contre des unités ordinaires et préférentielles de la holding acquéreuse, et certains RSU conservent les calendriers de vesting existants, avec une date de vesting importante le 10/11/2026.

Tomas Orozco, EVP Consumer Care von NeueHealth, Inc. (NEUE), meldete Transaktionen im Zusammenhang mit der Übernahme des Unternehmens am 10/02/2025. Die Einreichung zeigt eine Veräußerung von 29.325 Inhaber von Stammaktien und die Umwandlung/Übernahme ausstehender Restricted Stock Units in Muttergesellschafts-Einheiten als Teil einer Fusion, bei der der Emittent eine wholly-owned subsidiary wurde. Insgesamt wurden 230.490 RSUs (2.490; 180.000; 48.000) angepasst und unter den Awards der Muttergesellschaft fortgeführt; keine der Aktien oder daraus resultierenden Mutter-Common-Stock-Äquivalente werden nach den Transaktionen als vorteilhaft besessen gemeldet. Die Offenlegung vermerkt auch eine Rollover Agreement, die vorheriges Eigenkapital gegen Stamm- und Vorzugsaktien der Erwerbs-Holding austauschte, und dass bestimmte RSUs bestehende Vesting-Pläne beibehalten, mit einem wesentlichen Vesting-Datum am 10/11/2026.

Tomas Orozco، EVP العناية بالمستهلك من NeueHealth, Inc. (NEUE)، أبلغ عن معاملات مرتبطة بعملية الاستحواذ على الشركة في 10/02/2025. يُظهر الملف تصرّفاً بـ 29,325 سهماً من الأسهم العادية وتحويل/افتراض وحدات الأسهم المقيدة القائمة إلى وحدات الشركة الأم كجزء من اندماج أصبحت فيه الجهة المصدرة شركة تابعة مملوكة بالكامل. الإجمالياً، جرى تعديل 230,490 RSU (2,490؛ 180,000؛ 48,000) واستمرّت ضمن جوائز الكيان الأم؛ لا تُذكر أي من الأسهم أو النظائر الناتجة عن الأسهم العادية التابعة كمالكة بشكل مفيد بعد المعاملات. كما تشير الإفصاح إلى اتفاق التحويل الذي استبدل حقوق الملكية السابقة بوحدات عادية ومميزة من كيان الاستحواذ، وأن بعض RSU تبقي جداول الاستحقاق الحالية، مع تاريخ استحقاق مهم في 10/11/2026.

Tomas Orozco,NeueHealth, Inc. (NEUE) 的 客户关怀执行副总裁,在 10/02/2025 就公司的收购相关交易进行了报告。备案显示处置 29,325 股普通股,并将尚在限售的股票单位转换/承接为母公司单位,作为发行人并入成为全资子公司的合并的一部分。总计有 230,490 RSU(2,490;180,000;48,000)被调整并在母实体的奖励下继续;在交易后,任何股票或由此产生的母公司普通股等价物均未被报告为有益拥有。披露还注明一个 Rollover Agreement,将先前的股权兑换为收购控股实体的普通股和优先股,并且某些 RSU 维持现有的授予计划,重大归属日期为 10/11/2026

Positive
  • Equity continuity preserved through a Rollover Agreement converting issuer equity into holdings units
  • RSUs assumed and adjusted into parent-company awards, maintaining original terms and vesting schedules
Negative
  • Reported direct beneficial ownership reduced to zero following the reported disposition of 29,325 common shares
  • Large RSU block of 180,000 and an additional 48,000 remain subject to future vesting, creating concentration of future dilution or insider supply

Insights

Post-merger equity was rolled into the buyer's holdings; direct share ownership reported at zero.

The reporting person, an executive officer, contributed existing issuer equity into NH Holdings under a Rollover Agreement and the issuer merged into a Merger Sub controlled by NEA-affiliated funds. This preserved economic exposure via holdings units rather than direct public shares.

Dependencies include the terms of the Rollover Agreement and continued applicability of original award restrictions; investors should note the 10/11/2026 vesting milestone for a sizeable block of RSUs.

The filing documents share disposal and conversion of RSUs into parent-company equivalents tied to the acquisition.

The Form 4 records a discrete disposition of 29,325 common shares and the adjustment/assumption of RSUs totaling 230,490 into parent common-stock units. Each RSU remains subject to original vesting terms and some grants have accelerated or single-date vesting noted in the filing.

Key items to watch are the vesting schedule details (original installment schedules and the 10/11/2026 cliff for certain units) and any future filings that convert units into publicly traded shares or disclose distributions from the holdings vehicle.

Tomas Orozco, EVP Consumer Care di NeueHealth, Inc. (NEUE), ha riferito operazioni legate all'acquisizione della società in 10/02/2025. La dichiarazione mostra una cessione di 29.325 azioni ordinarie e la conversione/assunzione di unità azionarie vincolate rimanenti in unità controllate dalla casa madre come parte di una fusione in cui l'emittente è diventato una controllata interamente posseduta. In totale 230.490 RSU (2.490; 180.000; 48.000) sono stati adeguati e continuano sotto le stock award dell'entità madre; nessuna delle azioni o degli equivalenti di azioni ordinarie della capogruppo risultano detenuti in modo beneficio dopo le operazioni. La divulgazione segnala anche un Accordo di rollover che scambia capitale proprio precedente per azioni ordinarie e azion i privilegiate della holding acquirente, e che alcuni RSU mantengono i relativi piani di maturazione esistenti, con una data di maturazione rilevante 10/11/2026.

Tomas Orozco, EVP de Atención al Cliente de NeueHealth, Inc. (NEUE), informó transacciones relacionadas con la adquisición de la empresa en 10/02/2025. Los archivos muestran una disposición de 29,325 acciones ordinarias y la conversión/asunción de unidades restringidas de acciones en unidades de la empresa matriz como parte de una fusión en la que el emisor se convirtió en una subsidiaria de propiedad absoluta. En total se ajustaron y continuaron 230,490 RSU (2,490; 180,000; 48,000) bajo los premios de la entidad matriz; ninguna de las acciones o equivalentes de acciones comunes de la matriz resultantes se reportan como poseídas beneficiariamente después de las transacciones. La divulgación también señala un Acuerdo de rollover que intercambió capital previo por unidades comunes y preferentes de la holding adquirente, y que ciertos RSU conservan los calendarios de vesting existentes, con una fecha de vesting sustancial el 10/11/2026.

Tomas Orozco, NeueHealth, Inc. (NEUE)의 소비자 관리 부문 EVP가 회사의 인수와 관련된 거래를 10/02/2025에 보고했습니다. 공시는 합병의 일부로 발행인이 전액 소유 자회사가 된 경우에 해당하는 모회사 단위로의 이전/전환으로, 29,325 주의 보통주 처분 및 미확정 주식단위(RSU)의 전환/인수를 표시합니다. 총 230,490 RSU(2,490; 180,000; 48,000)가 조정되어 모회사 보상 하에서 계속되며, 거래 이후 어떤 주식이나 모회사 보통주 등가물도 유리하게 소유된 것으로 보고되지 않습니다. 또한 Rollover Agreement가 있어 이전 자본을 인수 보유 구조의 보통주 및 우선주로 교환했고, 일부 RSU는 기존 vesting 일정을 유지하며, 중요한 vesting 날짜는 10/11/2026입니다.

Tomas Orozco, EVP Consumer Care de NeueHealth, Inc. (NEUE), a signalé des transactions liées à l'acquisition de la société le 10/02/2025. Le document indique une cession de 29 325 actions ordinaires et la conversion/prise en charge des unités d’actions restreintes en unités de la société mère dans le cadre d’une fusion où l’émetteur est devenu une filiale à part entière. Au total, 230 490 RSU (2 490; 180 000; 48 000) ont été ajustés et poursuivis sous les récompenses de l’entité mère ; aucune des actions ou des équivalents d’actions ordinaires de la société mère ne sont déclarés comme détenus de manière bénéficiaire après les transactions. La divulgation mentionne également un Rollover Agreement qui échangeait les capitaux propres antérieurs contre des unités ordinaires et préférentielles de la holding acquéreuse, et certains RSU conservent les calendriers de vesting existants, avec une date de vesting importante le 10/11/2026.

Tomas Orozco, EVP Consumer Care von NeueHealth, Inc. (NEUE), meldete Transaktionen im Zusammenhang mit der Übernahme des Unternehmens am 10/02/2025. Die Einreichung zeigt eine Veräußerung von 29.325 Inhaber von Stammaktien und die Umwandlung/Übernahme ausstehender Restricted Stock Units in Muttergesellschafts-Einheiten als Teil einer Fusion, bei der der Emittent eine wholly-owned subsidiary wurde. Insgesamt wurden 230.490 RSUs (2.490; 180.000; 48.000) angepasst und unter den Awards der Muttergesellschaft fortgeführt; keine der Aktien oder daraus resultierenden Mutter-Common-Stock-Äquivalente werden nach den Transaktionen als vorteilhaft besessen gemeldet. Die Offenlegung vermerkt auch eine Rollover Agreement, die vorheriges Eigenkapital gegen Stamm- und Vorzugsaktien der Erwerbs-Holding austauschte, und dass bestimmte RSUs bestehende Vesting-Pläne beibehalten, mit einem wesentlichen Vesting-Datum am 10/11/2026.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Orozco Tomas

(Last) (First) (Middle)
9250 NW 36TH ST SUITE 420

(Street)
DORAL FL 33178

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NeueHealth, Inc. [ NEUE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
EVP, Consumer Care
3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/02/2025 D(1) 29,325 D (2) 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (3) 10/02/2025 D(1) 2,490 (4) (4) Common Stock 2,490 (5) 0 D
Restricted Stock Units (3) 10/02/2025 D(1) 180,000 (6) (6) Common Stock 180,000 (5) 0 D
Restricted Stock Units (3) 10/02/2025 D(1) 48,000 (7) (7) Common Stock 48,000 (5) 0 D
Explanation of Responses:
1. On October 2, 2025, NH Holdings 2025, Inc. ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and NH Holdings Acquisition 2025, Inc., a wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of December 23, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). Parent and Merger Sub are indirectly controlled by private investment funds affiliated with New Enterprise Associates, Inc.
2. Pursuant to the Rollover Agreement, dated as of September 17, 2025 (the "Rollover Agreement"), entered into by and among NH Holdings 2025 SPV, L.P. ("Holdings"), NH Holdings 2025, Inc., NH Holdings Acquisition 2025, Inc. and the Reporting Person, the Reporting Person contributed its shares of Issuer common stock, Series A Convertible Perpetual Preferred Stock ("Series A Preferred Stock") and Series B Convertible Perpetual Preferred Stock ("Series B Preferred Stock") to Holdings in exchange for Holdings common units, series A preferred units and series B preferred units on a one for one basis in accordance with the Rollover Agreement, and effective as of the effective time of the Merger (the "Effective Time").
3. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
4. The original grant of these restricted stock units vest in equal annual installments beginning on 3/6/23.
5. Each Issuer restricted stock unit ("RSU") outstanding immediately prior to the Effective Time was assumed and adjusted into a restricted stock unit with respect to a number of shares of common stock of Parent equal to the number of shares of Issuer common stock subject to such Issuer RSU and continued to be subject to the same terms and restrictions set forth in the Issuer equity plans and any applicable individual award agreement issued thereunder (including with respect to vesting).
6. All of these restricted stock units vest on 10/11/26.
7. The original grant of these restricted stock units vest in equal annual installments beginning on 3/11/24.
Remarks:
/s/ Eric Halverson for Tomas Orozco, Attorney-in-Fact 10/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did NEUE insider Tomas Orozco report on Form 4?

The Form 4 reports a disposition of 29,325 common shares and the assumption/adjustment of 230,490 RSUs into parent-company units as part of a merger on 10/02/2025.

Does Tomas Orozco still own NEUE shares after the merger?

Following the reported transactions, the filing shows 0 shares beneficially owned directly by the reporting person; prior equity was exchanged for holdings units under a Rollover Agreement.

How many restricted stock units were affected and when do they vest?

RSUs totaling 230,490 (2,490; 180,000; 48,000) were assumed/adjusted; certain grants vest in installments starting in 2023 or 2024, and a material tranche vests on 10/11/2026.

What triggered these changes in ownership reporting for NEUE (Form 4)?

The changes resulted from a merger in which the issuer became a wholly-owned subsidiary of NH Holdings 2025, Inc., and a Rollover Agreement that converted prior issuer equity into holdings units.

Who filed the Form 4 and when was it signed?

The Form 4 was filed on behalf of Tomas Orozco and signed by Eric Halverson as Attorney-in-Fact on 10/06/2025.
NeueHealth Inc

NYSE:NEUE

NEUE Rankings

NEUE Latest News

NEUE Latest SEC Filings

NEUE Stock Data

60.94M
7.28M
9.45%
58.37%
0.14%
Healthcare Plans
Hospital & Medical Service Plans
Link
United States
DORAL